COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN

被引：0
|
作者：
Morimoto, K. [1 ]
Moriwaki, K. [2 ]
Shimozuma, K. [3 ]
Nakayama, T. [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
  • [32] Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Liu, Xiaoxia
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [33] COST-EFFECTIVENESS OF PALLIATIVE CHEMOTHERAPY IN ADVANCED GASTROINTESTINAL CANCER
    GLIMELIUS, B
    HOFFMAN, K
    GRAF, W
    HAGLUND, U
    NYREN, O
    PAHLMAN, L
    SJODEN, PO
    ANNALS OF ONCOLOGY, 1995, 6 (03) : 267 - 274
  • [34] Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
    Ohno, Shinya
    Shoji, Ayako
    Hatake, Kiyohiko
    Oya, Naoko
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1130 - 1141
  • [35] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
    Lang, Wenwang
    Deng, Lian
    Lu, Meijun
    Ouyang, Ming
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1027 - 1042
  • [36] Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
    Luo, Xianmei
    Cai, Tingting
    Wu, Jinyan
    Li, Xingyu
    Wang, Xiaofan
    Ma, Haiying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [37] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [38] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [39] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China
    Zheng, Zhiwei
    Song, Xiaobing
    Qiu, Guodong
    Xu, Siqi
    Cai, Hongfu
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (03) : 433 - 440
  • [40] Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
    Sara Kaveh
    Nashmil Ghadimi
    Amirhossein Zarei Alvar
    Kamran Roudini
    Rajabali Daroudi
    Health Economics Review, 14 (1)
12345